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Cardiac N-Terminal
Pro–B-Type Natriuretic
Peptide Assay
The assessment of cardiac
Courtesy Idexx

disease in dogs and cats can
be a challenging task.

D

iagnostic techniques such as electrocardiography, radiography, and echocardiography are relatively expensive, time-consuming, and in the case of cardiac ultrasound, require specialized equipment and expertise. Cardiac
N-terminal pro–B-type natriuretic peptide (NT-proBNP) is a blood-based assay
that can assist practitioners in detection of underlying heart disease and differentiation of cardiac versus noncardiac etiology of respiratory signs.
The physiology of NT-proBNP is intriguing. In addition to its pump function,
the heart is also an endocrine organ, and natriuretic peptides, such as B-type
natriuretic peptide (BNP), are secreted by atrial and ventricular myocytes primarily in response to dilation or stretch.1,2 Cardiac NT-proBNP is a byproduct of
BNP production (Figure 1). The biologic actions of BNP are counter to those of
the renin-angiotensin-aldosterone system. That is, BNP elicits vasodilation, natriuresis, and diuresis.
Cardiac disease, including degenerative mitral valve disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy, is associated with elevated production of
BNP and, therefore, elevated formation of NT-proBNP.3-8 NT-proBNP is more
stable in circulation than BNP and can be detected using standard ELISA-based
technology. NT-proBNP is formed in a 1:1 ratio with BNP and can be used to
help detect heart disease and determine etiology of respiratory signs in both dogs
and cats.3-11

BNP = B-type natriuretic peptide; ELISA = enzyme-linked immunosorbent assay; NT-proBNP = N-terminal
pro–B-type natriuretic peptide

1

Schematic of NT-proBNP secretion
and release. Note that the biologically active hormone is actually BNP,
and NT-proBNP is a byproduct of its
formation. Due to NT-proBNP’s
greater stability in circulation, the
diagnostic assay tests for the NTproBNP molecule as opposed to BNP
itself. This method is valid because
NT-proBNP is produced in a 1:1 fashion with BNP.
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DIAGNOSTIC INDICATIONS
The differentiation of congestive heart failure
from primary respiratory disease in animals that
present with respiratory signs, such as coughing,
wheezing, increased respiratory effort, or emergent respiratory distress, can be challenging.
NT-proBNP is released in response to myocardial stretch and consequently is typically elevated in animals with congestive heart failure.
As a result, markedly elevated NT-proBNP at
time of presentation may help alert practitioners
to a high likelihood of heart failure (as opposed
to primary respiratory disease) as the cause of
clinical signs.
Heart Disease in Cats
The most common acquired heart diseases in
cats are hypertrophic and restrictive cardiomyopathy. These diseases present a unique diagnostic challenge because many cats with significant
disease have no clinical signs for long periods of
time. Moreover, physical examination findings
(including heart murmurs and gallops), which
are suggestive of underlying disease, can be difficult to detect in many animals.
Cats with plasma levels of NT-proBNP < 100
pmol/L are unlikely to be affected by clinically
significant heart disease. In patients with mild
elevations of plasma NT-proBNP levels (100
–270 pmol/L), further diagnostics, such as
echocardiography, are recommended if the clinical suspicion of heart disease is high. Plasma
NT-proBNP levels > 270 pmol/L indicate a
high likelihood of underlying heart disease; further workup is recommended.
False-positives and false-negatives can occur and
results of NT-proBNP assays should be interpreted in conjunction with history, physical
examination findings, and other diagnostic tests.
Most important, NT-proBNP testing reflects
current heart function, and a single normal
result does not preclude the possibility of disease
development at a future date. Therefore, NTproBNP testing is not recommended as a
screening tool in young cats of breeding age.

Heart Disease in Dogs
Dogs with degenerative mitral valve disease or
dilated cardiomyopathy generally have elevated
plasma NT-proBNP levels. It is important to
note that in older, small-breed dogs with no
clinical signs, the diagnosis of mitral valve disease is easily made by auscultation.
CONTINUES

Participate

in a Series of Case Studies

Test & Improve Your
Cardiac Diagnostic Skills
Participate in an online study designed
to test and improve your cardiac
diagnostic skills.
The purpose of this study is to
determine veterinarians’ accuracy when
diagnosing congestive heart failure
(CHF) or primary pulmonary disease as
the etiology of respiratory signs in dogs.
The hypothesis is that NT-proBNP assay
will help improve accuracy of diagnosis
and veterinarian confidence when used
in conjunction with traditional diagnostics, such as electrocardiography and
thoracic radiography.
The survey contains actual case data
from dogs and cats that presented for
evaluation of respiratory signs to 1 of 2
veterinary referral centers (University
of Pennsylvania and Tufts University).
Based on your evaluation of the diagnostic tests, you will determine a diagnosis
of CHF or primary respiratory disease
before and after disclosure of the
NT-proBNP results.
To obtain more information about the
study and to earn continuing education
credit, visit vetmedce.org.

There is a $35 fee per CE credit (assessed by the University of
Wisconsin CE program); participants can take up to 3 CE credits.
The survey is free for participants not receiving CE credit.
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Table.
NT-proBNP as a Diagnostic Tool for Heart Disease
NT-proBNP Plasma Level

Indication

Cats

‹ 100 pmol/L

Clinically significant heart disease
unlikely

100–270 pmol/L

Further diagnostics recommended if
clinical suspicion of heart disease is
high

› 270 pmol/L

High likelihood of underlying heart
disease; further workup recommended

Dogs

‹ 900 pmol/L

Clinically significant heart disease
unlikely

900–1800 pmol/L

Further diagnostics recommended if
clinical suspicion of heart disease is
high

› 1800 pmol/L

High likelihood of heart failure if
clinical signs are present

The severity of heart disease as assessed by clinical signs and heart size is moderately correlated
to the degree of NT-proBNP elevation. Dogs
with plasma NT-proBNP levels < 900 pmol/L
are very unlikely to be affected by clinically significant heart disease. If a dog has mildly elevated concentrations of plasma NT-proBNP
levels (900–1800 pmol/L) and the clinical presentation is suspicious for heart disease, further
workup, including thoracic radiographs or
echocardiography, is recommended. Plasma NTproBNP levels > 1800 pmol/L are severely elevated and the likelihood of heart failure is high
if clinical signs are present.
False-positives and false-negatives can occur and
results of NT-proBNP assays should be interpreted in conjunction with history, physical
examination findings, and other diagnostic tests.
Current diagnostic recommendations for dogs
and cats are summarized in the Table.
PROGNOSTIC INDICATIONS
An intriguing use of NT-proBNP assay involves
assessment of morbidity and mortality risk in
dogs with mitral valve disease. A recent study
reported that dogs with higher NT-proBNP
values had a greater risk of death due to cardiac
causes than dogs with lower values.12 This finding, along with those of others,13 suggests that
NT-proBNP assay may identify subpopulations
of dogs that would benefit from closer monitoring or more aggressive therapy. Future clinical
trials should help clarify the role of NT-proBNP
in identifying risk and guiding therapy in dogs
with mitral valve disease.

2
By virtue of its blood-based
characteristics, NT-proBNP
assay is relatively affordable
and easy to perform.

ADVANTAGES
The advantages of blood-based testing for disease are self-evident. The ease, rapidity, cost,
widespread availability, and objective results are
highly attractive (Figure 2). NT-proBNP assay
appears to provide objective and prognostic data
that is independent of conventional testing.
CONTINUES

NT-proBNP = N-terminal pro–B-type natriuretic peptide
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DISADVANTAGES
As with any diagnostic test, the results of NTproBNP assays should not be interpreted in isolation. This assay should be used in conjunction
with signalment, history, physical examination
findings, and, if indicated, other diagnostic
tests, such as radiography, echocardiography,
electrocardiography, blood pressure measurement, serum biochemistry, and thyroid assay. It
is important to note that concurrent renal disease or prerenal azotemia causes elevations in
NT-proBNP in both dogs and cats; in these
instances values should be interpreted cautiously.
The clinical value of a diagnostic test is framed
by a competing balance between sensitivity and
specificity (Figure 3). While a completely
dichotomous test (one that definitively says
either “yes” or “no”) would be the most desirous,
NT-proBNP, like many other blood-based
assays, produces a continuum of results, including normal, moderately elevated, and severely
elevated values. Both false-positive and falsenegative results can exist, especially in animals
with relatively mild disease7,14 or animals with
concurrent heart and respiratory ailments.9-11

3

Currently, the NT-proBNP assay is only available as a “send-out” assay and reporting of
results requires approximately 24 hrs. This limits
the utility of the assay in the emergent patient
where rapid clinical decision making and treatment is desired.
ECONOMIC IMPACT
Blood-based assays are generally much less
expensive than other diagnostic tests, such as
thoracic radiography and echocardiography.
Clinicians may find that performing a NTproBNP assay improves confidence and owner
compliance when deciding if more expensive
diagnostics should or should not be pursued.
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The NT-proBNP assay represents a new paradigm for the assessment of cardiac disease in
veterinary medicine, and as such, clinicians
should realize that additional data are needed to
completely understand the role of cardiac bloodbased testing. A variety of studies addressing
many important issues are underway.
See Aids & Resources, back page, for references
and suggested reading.

The clinical value of a diagnostic
test is a balance between sensitivity
and specificity. The challenge is to
find assays that maximize each of
these parameters.
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